SSRIs: Applications in inflammatory lung disease and implications for COVID-19.
Neuropsychopharmacol Rep
; 41(3): 325-335, 2021 09.
Article
in English
| MEDLINE | ID: covidwho-1306671
ABSTRACT
Selective serotonin reuptake inhibitors (SSRIs) have anti-inflammatory properties that may have clinical utility in treating severe pulmonary manifestations of COVID-19. SSRIs exert anti-inflammatory effects at three mechanistic levels (a) inhibition of proinflammatory transcription factor activity, including NF-κB and STAT3; (b) downregulation of lung tissue damage and proinflammatory cell recruitment via inhibition of cytokines, including IL-6, IL-8, TNF-α, and IL-1ß; and (c) direct suppression inflammatory cells, including T cells, macrophages, and platelets. These pathways are implicated in the pathogenesis of COVID-19. In this review, we will compare the pathogenesis of lung inflammation in pulmonary diseases including COVID-19, ARDS, and chronic obstructive pulmonary disease (COPD), describe the anti-inflammatory properties of SSRIs, and discuss the applications of SSRIS in treating COVID-19-associated inflammatory lung disease.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia
/
Selective Serotonin Reuptake Inhibitors
/
COVID-19
/
Anti-Inflammatory Agents
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Neuropsychopharmacol Rep
Year:
2021
Document Type:
Article
Affiliation country:
Npr2.12194
Similar
MEDLINE
...
LILACS
LIS